204 results
ARS
2023 FY
EW
Edwards Lifesciences Corp
26 Mar 24
Annual report to shareholders
4:09pm
to facilitate coronary access, factoring in the future needs of patients in the treatment of severe symptomatic aortic stenosis. The Edwards Pulmonic … with the physician community to generate groundbreaking data that has expanded access to patients of all risk profiles. In 2023, The PARTNER 3 Trial, which
DEFA14A
EW
Edwards Lifesciences Corp
26 Mar 24
Additional proxy soliciting materials
4:08pm
Council We endeavor to improve access to healthcare by transforming patient lives with breakthrough medical technologies and passionate engagement … Director (when applicable) ▪ Elimination of supermajority voting ▪ Adoption of majority voting in director elections ▪ Adoption of proxy access right ▪
DEFA14A
EW
Edwards Lifesciences Corp
26 Mar 24
Additional proxy soliciting materials
4:08pm
control number located in the shaded box above available when you access the website and follow the instructions. When requesting via the Internet … that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all
8-K
EX-99.1
iusm6fexs325olagnh
6 Feb 24
Edwards Lifesciences Reports Fourth Quarter Results
4:23pm
S-3ASR
xqb2om
21 Jul 22
Automatic shelf registration
7:05pm
8-K
EX-10.1
ejnmxpkvm5lvz
21 Jul 22
Entry into a Material Definitive Agreement
4:20pm
DEFA14A
ox054alr6y9qqxi20
22 Mar 22
Additional proxy soliciting materials
4:06pm
DEFA14A
mmavyngrxxlf0tmxan
22 Mar 22
Additional proxy soliciting materials
4:04pm